1
                                                                    Exhibit 99.1

FOR IMMEDIATE RELEASE

COMPANY CONTACT:    Carol Coburn
                    (860)870-6112, extension 317
                    BIO.PLEXUS@SNET.NET

BIO-PLEXUS WINS SHAREHOLDER APPROVAL OF FINANCING

VERNON, Conn.--(BUSINESS WIRE)--May 1, 2000--At a special meeting of
stockholders, Bio-Plexus obtained stockholder approval for the $17.5 million
financing with entintities affiliated with Appaloosa Management, L.P. of
Chatham, New Jersey. At the meeting, Bio-Plexus' stockholders also approved an
amendment to Bio-Plexus' certificate of incorporation increasing the number of
authorized shares of common stock from 25 million to 40 million and an amendment
to Bio-Plexus' 1991 Long Term Incentive Plan which raised to 2.5 million the
number of shares of Common Stock subject to the plan.

Following the stockholders meeting, Bio-Plexus and Appaloosa consummated the
financing. In addition, John S. Metz assumed the role of President and Chief
Executive Officer. He was also appointed to the Board of Directors.

"Our investors showed strong support for the financing," Metz commented. "With
about 98% of the vote in favor of the financing, they have sent a clear message
that they are behind management's plan to dramatically increase sales efforts
and introduce new products to the market. The financing should clearly help us
penetrate the changing needle market with Punctur-Guard," he added.

Bio-Plexus, Inc. (NASDAQ: BPLX - news), designs, develops, manufactures and
holds U.S. and international patents on safety medical needles and other
products under the PUNCTUR-GUARD(R), DROP-IT(R), and PUNCTUR-GUARD
REVOLUTION(TM) brand names. In studies by the Centers for Disease Control
(January 1997) and ECRI, (Health Devices, June 1998 and October 1999)
Punctur-Guard needles ranked highest of all devices studied. Accidental
needlesticks number about one million per year in the United States and can
result in the transmission of deadly diseases including HIV and Hepatitis B and
C.

NOTE: THIS PRESS RELEASE MAY CONTAIN FORWARD-LOOKING STATEMENTS AS DEFINED UNDER
FEDERAL SECURITIES LAWS, AS AMENDED. FORWARD-LOOKING STATEMENTS MAY BE
IDENTIFIED BY THE USE OF SUCH TERMINOLOGY AS "BELIEVES," "EXPECTS," "MAY,"
"WILL," "SHOULD," "ANTICIPATES" OR DERIVATIONS OR NEGATIVES THEREOF OR
COMPARABLE TERMINOLOGY, OR DISCUSSIONS OF STRATEGY THAT INVOLVES RISKS AND
UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE
PROJECTED IN THE FORWARD-
   2
LOOKING STATEMENTS AS A RESULT OF, AMONG OTHER FACTORS, GENERAL ECONOMIC
CONDITIONS AND GROWTH IN THE SAFETY MEDICAL PRODUCTS INDUSTRY, COMPETITIVE
FACTORS AND PRICING PRESSURES, CHANGES IN PRODUCT MIX, PRODUCT DEMAND, RISK OF
DEPENDENCE ON THIRD PARTY SUPPLIERS AND FINANCIERS, ABILITY TO OBTAIN FINANCING,
AS WELL AS OTHER FACTORS DESCRIBED FROM TIME TO TIME IN THE COMPANY'S PERIODIC
REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION OR DISCUSSED IN OTHER
PRESS RELEASES ISSUED BY THE COMPANY.

- --------------------------------------------------------------------------------
2000